menu search

Infinity stone ventures updates on fall drill program at its rockstone graphite project

Infinity Stone Ventures Corp (CSE:GEMS) has provided an update on the fall drill program at its Rockstone Graphite project located near Thunder Bay...

December 6, 2022, 6:47 am

American eagle says second nak hole adds 'additional confidence' to drill program

American Eagle Gold Corp (TSX-V:AE) told investors that assay results from the second hole of the 2022 program on its NAK copper-gold porphyry projec...

December 5, 2022, 8:01 am

Northwest copper reports first batch of stardust drilling results from 2022 program

NorthWest Copper Corp (TSX-V:NWST) has released the first results from the 2022 Stardust drilling program, which includes 44.20 metres (m) at 1.31% co...

November 16, 2022, 8:23 am

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts ha...

November 12, 2022, 9:30 pm

American eagle intersects broad, high-grade mineralization from surface in first hole in nak project in babine copper-gold district

American Eagle Gold Corp (TSX-V:AE) reported impressive assay results from NAK22-01, the first hole of its 2022 program on its flagship NAK copper-por...

November 7, 2022, 9:34 am

Kootenay silver drills more high-grade silver at its columba project in mexico

Kootenay Silver Inc. (TSX-V:KTN) has announced the final batch of results from the Phase 4 drilling program at its Columba high-grade silver project i...

September 8, 2022, 9:33 am


Search within

Pages Search Results: